Dr. Zev Wainberg's clinical interests include designing GI (gastroenterology) cancer clinical trials. He is particularly interested in the development and testing of new targeted therapies for the treatment of colon cancer, gastric cancer and esophagus cancer.
Wainberg's laboratory and translational research involves gene expression patterns in a variety of GI cancers and the molecular profiling of these cancers for novel therapies. His research also involves the targeting of GI and prostate cancers with new antibody technologies.
Selected Cancer-Related Publications:
Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Jan;5(5):363-7.
Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther. 2006 Nov;6(11):1229-35.
Brenner BG, Wainberg Z. Heat shock proteins: novel therapeutic tools for HIV-infection? Expert Opin Biol Ther. 2001 Jan;1(1):67-77.
Wainberg Z, Oliveira M, Lerner S, Tao Y, Brenner BG. Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following acute infection with human immunodeficiency virus type-1. Virology. 1997 Jul 7;233(2):364-73.